Specifically, promoter-rich methylated cytosine residues [41], non-acetylated histone 3 lysine 27 in enhancer regions [42], and chromatin interaction of the histone methyltransferase, EZH2 [43], have all been identified as mechanisms of epigenetic repression for FBP1 in liver cancer. This evidence concerns the gene EZH2 and liver cancer.